SightfileU.S. market data from official filings

ARBUTUS BIOPHARMA CORP (ABUS)

Name: ARBUTUS BIOPHARMA CORP (ABUS) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001447028 · EDGAR filings · Updated 2026-07-16

ARBUTUS BIOPHARMA CORP (ABUS) has reported institutional ownership of 71.1%, with 168 institutional managers holding positions valued at $625.4M per the latest 13F reporting period.

Institutional ownership

71.1%

Institutional managers

168

Reported 13F value

$625.4M

Insider activity

2 trans.

$0 net flat

Latest updates

2026-07-16 — Current report (8-K) filed
2026-06-10 — Insider transaction reported (Form 4)
2026-06-10 — Insider transaction reported (Form 4)
2026-06-05 — Employee-plan registration (S-8) filed
2026-05-27 — Current report (8-K) filed
2026-05-15 — SCHEDULE 13G/A filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ARBUTUS BIOPHARMA CORP has 168 institutional holders and institutional ownership of 71.1%.

Insider activity

Insiders reported 2 transactions (0 buys, 0 sells) across 2 reporting insiders, with a net reported value of $0.

Related companies

TALKSPACE INC (TALK) · AVANOS MEDICAL INC (AVNS) · AMPHASTAR PHARMACEUTICALS INC COM (AMPH) · AKTIS ONCOLOGY INC (AKTS) · REPLIMUNE GROUP INC (REPL) · STEVANATO GROUP S P A (STVN)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-16.